Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Miranda Hardee

Urology Austin, TX Medical Doctor

NPI 1912151150 CMS profile 131801

11410 Jollyville Rd Ste 1101, Austin, TX 78759

Open in the dashboard

General payments

$8,705

438 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Miranda Hardee of Austin, TX is reported in the CMS Open Payments database as having received $8,705 across 438 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,689 64
2024 General $1,499 75
2023 General $1,487 76
2022 General $1,029 57
2021 General $1,211 60
2020 General $846 50
2019 General $945 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Miranda Hardee
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Miranda Hardee were reported at $1,689. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Miranda Hardee Urology median Middle half National median
2019 $945 $480 $147–$1,201 $163
2020 $846 $246 $87–$645 $114
2021 $1,211 $358 $111–$1,000 $132
2022 $1,029 $476 $143–$1,263 $149
2023 $1,487 $560 $168–$1,461 $160
2024 $1,499 $563 $170–$1,464 $164
2025 $1,689 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,294 63 payments
  2. Janssen Biotech, Inc. $831 44 payments
  3. Astellas Pharma US Inc $642 37 payments
  4. Medtronic, Inc. $551 12 payments
  5. Sumitomo Pharma America, Inc. $506 29 payments
  6. Allergan Inc. $503 34 payments
  7. Antares Pharma, Inc. $403 21 payments
  8. Pfizer Inc. $367 20 payments
  9. Olympus America Inc. $307 14 payments
  10. Dendreon Pharmaceuticals LLC $240 9 payments
  11. Other $3,062 155 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,442 428 payments
  2. Education $264 10 payments
Products named General payments · program years 2019–2025
  1. BOTOX Botox Therapeutic $925 42 payments
  2. ERLEADA $786 42 payments
  3. BOTOX Hyperhydrosis $659 43 payments
  4. XTANDI $606 33 payments
  5. GEMTESA $578 41 payments
  6. INTERSTIM $391 9 payments
  7. MYRBETRIQ $312 22 payments
  8. iTIND System $307 14 payments
  9. ORGOVYX $258 14 payments
  10. XYOSTED $244 13 payments
  11. Other $4,695 220 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

2,792

Median for Urology: 1,053

Drug cost

$487,782

Median for Urology: $101,464

Branded share of claims

41.9%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 230 $208,964
Myrbetriq Mirabegron Brand 185 $161,583
Mirabegron Er Mirabegron Brand 69 $40,146
Estradiol Generic 358 $24,641
Fosfomycin Tromethamine Generic 42 $10,259
Methenamine Hippurate Generic 136 $6,989
Solifenacin Succinate Generic 117 $6,892
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 301 $6,578
Yuvafem Estradiol Brand 31 $3,134
Fesoterodine Fumarate Er Fesoterodine Fumarate Brand 24 $2,893

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 83 billing codes

Paid by Medicare

$247,813

Of which drugs: $40,815

Medicare patients

627

Average age 75

Services billed

14,440

469 women, 158 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 53%
Ischemic heart disease 31%
Diabetes 24%
Depression 24%
Osteoporosis 24%
Cancer 20%
Chronic kidney disease 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 37 8,000 $39,818
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 15 1,500 $157

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $253
$253 — 8,000
GEMTESA
  • Sumitomo Pharma America, Inc. $176
$176 230 —
ERLEADA
  • Janssen Biotech, Inc. $132
$132 — —
ORGOVYX
  • Sumitomo Pharma America, Inc. $97
  • PFIZER INC. $19
$115 — —
XYOSTED
  • Antares Pharma, Inc. $65
$65 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

438 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record